Intensity Therapeutics, Inc. financial data

Symbol
INTS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1 Enterprise Drive, Suite 430, Shelton, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 316 %
Debt-to-equity 40.6 %
Return On Equity -210 %
Return On Assets -149 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.9M shares +1.16%
Common Stock, Shares, Outstanding 13.9M shares +1.13%
Entity Public Float 22M USD
Common Stock, Value, Issued 1K USD -27.1%
Weighted Average Number of Shares Outstanding, Basic 13.8M shares +1.05%
Weighted Average Number of Shares Outstanding, Diluted 13.8M shares +1.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.3M USD +59.1%
General and Administrative Expense 6.41M USD +24.6%
Operating Income (Loss) -16.7M USD -43.3%
Net Income (Loss) Attributable to Parent -16.3M USD -50.8%
Earnings Per Share, Basic -0.34 USD/shares -47.1%
Earnings Per Share, Diluted -0.34 USD/shares -47.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.78M USD -58.4%
Marketable Securities, Current 8.96M USD
Cash, Cash Equivalents, and Short-term Investments 6.3M USD
Other Assets, Current 6K USD -92.1%
Assets, Current 3.79M USD -77.2%
Operating Lease, Right-of-Use Asset 128K USD -16.1%
Other Assets, Noncurrent 1.3M USD +4464%
Assets 5.21M USD -69%
Accounts Payable, Current 540K USD +50.7%
Employee-related Liabilities, Current 616K USD
Accrued Liabilities, Current 1.75M USD +393%
Liabilities, Current 2.32M USD +220%
Operating Lease, Liability, Noncurrent 117K USD -19.3%
Other Liabilities, Noncurrent 0 USD
Liabilities 2.43M USD +169%
Retained Earnings (Accumulated Deficit) -63.6M USD -34.3%
Stockholders' Equity Attributable to Parent 2.78M USD -82.5%
Liabilities and Equity 5.21M USD -69%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.37M USD -385%
Net Cash Provided by (Used in) Financing Activities 8K USD -96.1%
Net Cash Provided by (Used in) Investing Activities 3.26M USD
Common Stock, Shares Authorized 135M shares 0%
Common Stock, Shares, Issued 13.9M shares +1.13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD -57.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.78M USD -58.4%
Deferred Tax Assets, Valuation Allowance 12M USD +18.7%
Deferred Tax Assets, Gross 12M USD +18.7%
Operating Lease, Liability 145K USD -6.72%
Lessee, Operating Lease, Liability, to be Paid 167K USD
Operating Lease, Liability, Current 28K USD +165%
Lessee, Operating Lease, Liability, to be Paid, Year Two 37K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 36K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 39K USD
Deferred Tax Assets, Operating Loss Carryforwards 8.61M USD +6.92%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 39K USD
Operating Lease, Payments 17K USD
Additional Paid in Capital 66.4M USD +4.94%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39K USD +30%
Share-based Payment Arrangement, Expense 2.65M USD +37.6%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares